2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 148

Lack of Screening By Rheumatologists and Primary Care Physicians for Childhood Sexual Abuse in Patients with Fibromyalgia-Depression Overlap: An Unrecognized Crisis?
Abstract Number: 149

Effect of Vitamin D Supplementation in Chronic Widespread Pain: A Systematic Review and Meta-Analysis
Abstract Number: 150

Effects of Taping Therapy in the Management of Fibromyalgia: A Randomized Controlled Study
Abstract Number: 151

Prevalence of Fibromyalgia in Nurses; A Cross Sectional Study
Abstract Number: 152

Patients Failing to Fulfill 2016 Criteria for Fibromyalgia Represent a Truly Different Population Subset
Abstract Number: 153

Prevalence of Fibromyalgia in Physician in Training; A Cross Sectional Study
Abstract Number: 154

Frequency of Fibromyalgia in Patients with Antiphospholipid Syndrome. a Cross-Sectional Study
Abstract Number: 155

Xerostomia in Patients with Fibromyalgia
Abstract Number: 156

Unexpectedly High Prevalence of Immunoglobulin Deficiency in Fibromyalgia – II
Abstract Number: 157

A Systematic Review of the Upper Limb Soft Tissue Comorbidities in Patients with Type 2 Diabetes Mellitus
Abstract Number: 158

Is Lu Eight-Brocades Exercise Beneficial for Patients with Fibromyalgia?
Abstract Number: 159

The Use of “Fibromyalgia Rapid Screening Tool” for Detection of Fibromyalgia in Patients with Chronic Arthritis Treated with Full and Tapered Biological Disease-Modifying Antirheumatic Drugs
Abstract Number: 160

Fibromyalgia Screening Form in the Diagnosis of Concomitant Fibromyalgia
Abstract Number: 161

The Effectiveness of Medications for Fibromyalgia Based on Patient Experiences
Abstract Number: 162

Depression Versus Frustration

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].